Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

  title={Efficacy and safety of anti‐amyloid‐$\beta$ immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis},
  author={Jiajie Mo and Jin-Yu Li and Zheng Yang and Zhou Liu and Jin-Shan Feng},
  journal={Annals of Clinical and Translational Neurology},
  pages={931 - 942}
To review the optimality and safety of different anti‐Amyloid‐β(Aβ) immunotherapies for Alzheimer's disease (AD). Published randomized controlled trials were comprehensively reviewed from electronic databases (Cochrane library, Embase, Pubmed, and Google scholar). Pooled outcomes as mean difference or odds ratio values with 95% confidence interval were reported. The network estimates with confidence and predictive intervals for all pairwise relative effects was evaluated. Optimal intervention… 

Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis

From current evidence, anti-Aβ interventions are unlikely to have an important impact on slowing cognitive or functional decline, and a benefit from drugs that increase clearance, if real, is very small.

Aducanumab for the treatment of Alzheimer's disease: a systematic review.

Aducanumab has been reported to affect two main pathophysiologic hallmarks of Alzheimer's disease, and future studies addressing aducanumab's efficacy and safety are suggested to confirm that the benefit of this drug outweighs the risk.

Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials

The results suggest that the risk-benefit profile of mAbs remains unclear and research should focus on clarifying the effect of amyloid on cognitive decline, providing data on treatment response rate, and accounting for minimal clinically important difference.

Effect of antiamyloid-β drugs on Alzheimer’s disease: study protocol for a systematic review and meta-analysis

The effect of anti-Aβ antibodies versus placebo on the clinical efficacy, biomarkers, neuroimaging and safety in different stages of AD, as well as the factors that may affect the efficacy, are studied.

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

Future disease-modifying trials (DMTs) for AD should be conducted in asymptomatic, Aβ-positive individuals and potential additive and/or synergistic benefits focusing on anti-Aβ and anti-tau drug combinations merit further investigation.

Rodent Models of Amyloid-Beta Feature of Alzheimer’s Disease: Development and Potential Treatment Implications

This review focuses on transgenic rodent models used to study amyloid-beta pathology in AD and discusses the advantages and limitations of these models and their potential therapeutic implications for AD.

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Control studies regarding prevention and treatment of ARIA are lacking, but anecdotal evidence suggests that a pulse of intravenous corticosteroids may be of benefit, as well as a course of anticonvulsant for seizures.

Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review.

Alzheimer's disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role of caregivers. This debilitating disease reportedly

The β‐secretase (BACE) inhibitor NB‐360 in preclinical models: From amyloid‐β reduction to downstream disease‐relevant effects

The BACE‐1 inhibitor NB‐360, although not a clinical compound, turned out to be a valuable pharmacological tool to investigate the effects of Bace‐1 inhibition on the deposition of different Aβ species in amyloid precursor protein (APP) transgenic mice.



Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Immunotherapeutic agents have been relatively well tolerated, with some promise for cognitive improvements if the occurrence of ARIA can be mitigated, and the Mini-Mental State Examination showed a small statistically significant improvement.

Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

Considering the lack of clinical efficacy, combined with the significant association with serious adverse events, bapineuzumab should not be used to treat patients with mild to moderate Alzheimer’s disease.

Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.

Information is clarified and updated in the review article by Wilcock and Colton recently published in JAD that the clinical trials investigating ACC-001 (an active immunotherapy under development by Wyeth and Elan) had failed and are currently ongoing.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers.

New developments of clinical trial in immunotherapy for Alzheimer's disease.

Recent advances in clinical trials involving immunotherapy for AD are reviewed, showing a high incidence of amyloid-related imaging abnormalities in patients treated with some monoclonal antibodies and several phase 3 clinical trial findings of immunization targeting Aβ were negative.

RETRACTED ARTICLE: Gantenerumab for the treatment of Alzheimer's disease

Gantenerumab appears capable of reducing the cerebral β-amyloid peptide burden in patients with Alzheimer's disease, and its ability to slow disease progression remains uncertain because no clinical data are available at present.

Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.

This is the first study to prospectively use optimized scales as primary endpoints and to demonstrate the superior power of optimized scales and composites in early disease.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

Bapineuzumab has been shown to reduce Aβ burden in the brain of AD patients, however, its preliminary cognitive efficacy appears uncertain, particularly in ApoE ε4 carriers, and vasogenic edema may limit its clinical use.